

Valeant Pharmaceuticals to Acquire Beauty Product Maker

Deal to Buy Solta Medical Valued At \$250 Million, a 40% Premium

By: Everdeen Mason
Dec. 16, 2013 8:40 a.m. ET

[Valeant Pharmaceuticals International](#) agreed to acquire medical device company [Solta Medical Inc.](#) for \$250 million to increase its offerings in the growing market for beauty products.

Valeant will offer Solta shareholders \$2.92 a share, a 40% premium to its Friday close of \$2.09. The stock hasn't traded above the offer price since October 2012. Through Friday's close, Solta's stock is down 23% over the past year.

Solta is known for developing medical devices for aesthetics, including skin tightening treatment Fraxel, dermatologic product Clear + Brilliant and fat loss system Liposonix. While the market for dermatologic treatments has grown, the company has posted revenue below analyst expectations in recent periods. Solta recently unveiled restructuring plans in November that includes a reduction in workforce.

Meanwhile, Valeant seeks to add Solta's products to its existing portfolio of skin-care treatments.

Solta's "aesthetic devices are a natural fit with Valeant's facial injectables, professional skin care products and physician dispensed products," Valeant Chief Executive J. Michael Pearson said.

The deal is expected to close in the fiscal first quarter and will immediately add to Valeant's earnings per share, the company added.

Valeant has been making acquisitions to boost its profile in the eye-care and medical device industries. Most recently, the company acquired Montreal-based Bausch & Lomb Holdings Inc. for \$8.7 billion.

Write to Everdeen Mason at everdeen.mason@wsj.com